Drug reference
Hyperphosphataemia in patients with chronic kidney disease on haemodialysis or peritoneal dialysis ▶BY MOUTH ▶Adult: Initially 1.5 g daily in 3 divided doses, dose to be taken with meals, then adjusted in steps of 500 mg every 2–4 weeks, dose adjusted according to serum- phosphate concentration; maintenance 1.5–2 g daily in divided doses; maximum 3 g per day
PDF page 1138
Haemochromatosis. iron accumulation disorders
PDF page 1138
Gastric disorders. hepatic disorders. major gastrointestinal surgery. peritonitis in the last 3 months
PDF page 1138
▶Common or very common Constipation. diarrhoea. gastrointestinal discomfort. gastrointestinal disorders. nausea. product taste abnormal. tooth discolouration. vomiting ▶Uncommon Dysphagia. dyspnoea. electrolyte imbalance. fatigue. headache. skin reactions. tongue discolouration SIDE-EFFECTS, FURTHER INFORMATION Discoloured faeces may mask the visual signs of gastrointestinal bleeding.
PDF page 1138
Manufacturer advises use only if potential benefit outweighs risk—no information available.
PDF page 1138
Manufacturer advises avoid—no information available.
PDF page 1138
Velphoro ® tablets must be chewed or crushed, not swallowed whole.
PDF page 1138
There can be variation in the licensing of different medicines containing the same drug. Chewable tablet ▶Velphoro (Vifor Fresenius Medical Care Renal Pharma UK Ltd) Iron (as Sucroferric oxyhydroxide) 500 mg Velphoro 500mg chewable tablets | 90 tablet P £179.00 DT = £179.00 1.4b Hypophosphataemia ELECTROLYTES AND MINERALS › PHOSPHATES
PDF page 1138
Patients or carers should be counselled on administration of sucroferric oxyhydroxide tablets and advised that this medication can cause discoloured black stools.
PDF page 1138
Initially 1.5 g daily in 3 divided doses, dose to be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1138
